Glenmark Expands U.S. Injectables Portfolio with Launch of Generic Olanzapine Injection
Glenmark Pharmaceuticals Inc., USA, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited, has announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial in the United States. The newly launched product is bioequivalent and therapeutically equivalent to Zyprexa® IntraMuscular Injection 10 mg/vial (NDA 021253) marketed by Cheplapharm Registration GmbH.




















